ArQule, Inc. (NASDAQ:ARQL)
CAPS Rating:
A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics.
RSS Headlines
Fool UK
Recs
Hoping the market notices ARQL is well positioned to possibly ride on the coat-tails of Exel's drug XL184...